2nd Quarter - Report
AEGERION PHARMACEUTICALS A NOVELION THERAPEUTICS COMPANY for AEGERION PHARMACEUTICALS A NOVELION THERAPEUTICS COMPANY
Income
—
Expenses
$93,625
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Health Care Reform Rare Diseases Medicare and Medicaid
Foreign entity interest: That the policy climate in the US continues to support ultra-rare disease patient access to therapies in their healthcare coverage.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL J EGING | — |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| NOVELION THERAPEUTICS | Canada | Canada | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.